Shares of AstraZeneca, 0.93% were down 3.4% in trading on 20 July after a medical journal published a study that found the company’s Covid-19 vaccine candidate produced antibody and T-cell responses in participants in a Phase 1/2 clinical trial.
AstraZeneca is developing the experimental vaccine with the University of Oxford; the study was published in The Lancet.